Why the study?
Does higher epicardial fat volume measured by MDCT predict increased long-term major adverse cardiac events in patients with moderate cardiovascular risk?
Does higher epicardial fat volume measured by MDCT predict increased long-term major adverse cardiac events in patients with moderate cardiovascular risk?
Higher epicardial fat volume measured by MDCT is associated with an increased risk of long-term major adverse cardiac events in patients with moderate cardiovascular risk.
Answers are grounded in this paper and cite their sources.
May enhance MACE risk prediction in moderate-risk patients; leaves open whether MDCT epicardial fat assessment should enter clinical practice.
We investigated the relationship between epicardial fat volume (EFV) measured by multislice computed tomography (MDCT) and long-term major adverse cardiac events (MACEs). Consecutive patients (n = 564) were enrolled in this retrospective study. Patients were divided into tertiles according to EFV. Patients were followed up for an average of 18 months. Patients in each tertile were similar in terms of gender and risk factors. Patients with greater EFV in the third group were more likely to be overweight (P = .001) and older (P = .001). High-density lipoprotein cholesterol levels were relatively lower in the third tertile (45 ± 9, 45 ± 11, and 43 ± 9 mg/dL, respectively; P = .018). The third group had a significantly higher rate of myocardial infarction (0.6%, 1.1%, and 3.7%, respectively; P = .043). The incidence of MACEs during the follow-up period was highest in the third group 15.9% (4.1%, 7.7%, and 15.9%, respectively; P = .001). Epicardial fat volume measured by MDCT was associated with increased long-term cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Ulucan et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: